Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Post-Marketing Pharmacovigilance And Medical Information Market Expansion From $7.71 Billion In 2026 To $11.89 Billion In 2030
The market for post-marketing pharmacovigilance and medical information has experienced swift expansion in recent times. Valued at $6.9 billion in 2025, it is projected to reach $7.71 billion by 2026, reflecting a compound annual growth rate (CAGR) of 11.7%. Factors driving growth during the historical period include insufficient post-marketing surveillance infrastructure, dependence on manual adverse drug reaction (ADR) reporting, escalating regulatory demands for drug safety, a rising volume of new drug approvals, and the absence of integrated hospital data systems.
The market for post-marketing pharmacovigilance and medical information is projected to undergo rapid expansion over the coming years, reaching an estimated value of $11.89 billion by 2030, which corresponds to a compound annual growth rate (CAGR) of 11.4%. This anticipated growth during the forecast period is driven by several key factors, including the integration of artificial intelligence and machine learning algorithms into signal detection, the adoption of longitudinal patient data analysis, the expansion of monitoring linked to disease registries, an increase in digital app-based reporting, and heightened investments in real-time pharmacovigilance technologies. Prominent trends shaping this period encompass the growing adoption of electronic health record (EHR) mining, a rise in the use of real-time adverse drug reaction (ADR) monitoring systems, an expansion of reporting based on risk populations and therapeutic classes, the broadening of cohort event monitoring for users of new drugs, as well as the integration of digital and mobile platforms for pharmacovigilance reporting.
Download A Free Sample Report For Comprehensive Market Insights:
Post-Marketing Pharmacovigilance And Medical Information Market Growth Momentum: Which Factors Are Influencing Demand?
The increasing frequency of adverse drug reactions is anticipated to boost the expansion of the post-marketing pharmacovigilance and medical information market moving forward. Adverse drug reactions involve detrimental or unintended effects arising from medication use at prescribed doses for prevention, diagnosis, or treatment. This rise is driven by the growing elderly population requiring management of multiple chronic conditions, which often involves concurrent use of various drugs, thereby elevating the risk of harmful interactions and unforeseen side effects. Post-marketing pharmacovigilance and medical information aid in addressing these reactions by identifying, monitoring, and disseminating data on potential side effects after a drug’s release, ensuring its ongoing safety and efficacy. As an example, in January 2023, Navikenz, a US-based AI-focused IT services firm, reported that adverse drug reactions cause an estimated 200,000 to 400,000 fatalities annually in the United States, surpassing the combined death toll from stroke and diabetes, with about 2.7 million cases each year leading to over 100,000 hospitalizations and more than 15,000 deaths. Consequently, the rising prevalence of adverse drug reactions is fueling the growth of the post-marketing pharmacovigilance and medical information market.
Post-Marketing Pharmacovigilance And Medical Information Market Segment Landscape: Which Areas Lead Market Development?
The post-marketing pharmacovigilance and medical information market covered in this report is segmented –
1) By Type: Spontaneous Reporting, Intensified Adverse Drug Reaction (ADR) Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, Electronic Health Record (EHR) Mining
2) By Publication Type: Books, Online Media, Journals
3) By End User: Hospitals, Research Organizations, Other End-Users
Subsegments:
1) By Spontaneous Reporting: Consumer Reporting, Healthcare Professional Reporting, Regulatory Authority Reporting, Pharmaceutical Company Reporting, Digital App-Based Reporting
2) By Intensified Adverse Drug Reaction (ADR) Reporting: Hospital-Based Surveillance, Program-Specific Monitoring, Disease-Specific Monitoring, Product-Specific Monitoring, Real-Time Monitoring Systems
3) By Targeted Spontaneous Reporting: Risk Population-Based Reporting, Therapeutic Class-Based Reporting, Adverse Drug Reaction Focused Reporting, Region-Specific Reporting, Healthcare Setting-Specific Reporting
4) By Cohort Event Monitoring: Prospective Cohort Monitoring, Retrospective Cohort Monitoring, Active Follow-Up Monitoring, New Drug User Monitoring, Disease Registry-Linked Monitoring
5) By Electronic Health Record (EHR) Mining: Natural Language Processing-Based Mining, Artificial Intelligence (AI) And Machine Learning Algorithms, Rule-Based Signal Detection, Longitudinal Patient Data Analysis, Integrated Hospital Data Systems
Post-Marketing Pharmacovigilance And Medical Information Market Trends Reshaping Industry Growth
Major players in the post-marketing pharmacovigilance and medical information market are concentrating on creating sophisticated tools, including AI-enhanced pharmacovigilance workflows, to improve the precision of adverse event detection and facilitate real-time safety surveillance for superior patient results. These AI-powered workflows leverage artificial intelligence to automate drug safety surveillance, allowing for quicker identification of adverse events and strengthened regulatory adherence. As an example, in January 2024, PubHive Ltd., a UK-based provider of cloud-based software-as-a-service (SaaS) solutions, unveiled a centralized Summary of Product Characteristics (SmPC) management system designed for life science firms and research entities. This system gathers vital drug safety data into a single, easily navigable repository, automates literature tracking and regulatory submissions, boosts team collaboration, and simplifies compliance tasks using advanced AI features. Consequently, pharmacovigilance teams can function with greater efficiency and foresight, upholding patient safety while meeting regulatory requirements.
Post-Marketing Pharmacovigilance And Medical Information Market Industry Leaders And Market Competition
Major companies operating in the post-marketing pharmacovigilance and medical information market are Accenture plc, Sanofi S.A., Capgemini SE, Merck & Co. Inc., Cognizant Technology Solutions Corporation, IQVIA Holdings Inc., HCL Technologies Limited, ICON plc, Syneos Health Inc., Genpact Limited, Parexel International Corporation, Avalere Health LLC, Quanticate Limited, Inizio Consulting LLC
Access The Complete Post-Marketing Pharmacovigilance And Medical Information Market Report:
Post-Marketing Pharmacovigilance And Medical Information Market Largest Region By Revenue And Market Share
North America was the largest region in the post-marketing pharmacovigilance and medical information market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-marketing pharmacovigilance and medical information market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model